3 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMORecruiting
Clinical feasibility of the urine collection device, indicated by staff and parents.
Approved WMORecruiting
Objective: 1. Investigate the prevalence of ATTR in patients undergoing TAVR in the Netherlands.2. To determine whether ATTR influences the effectiveness of TAVR treatment on LV dysfunction.